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Abstract 
Background/aims: Previous evidences have shown the presence of a prolonged and exaggerated postprandial 
response in type 2 diabetes mellitus (T2DM) and its relation with an increase of cardiovascular risk. However, the 
response in prediabetes population has not been established. The objective was to analyze the degree of postpran‑
dial lipemia response in the CORDIOPREV clinical trial (NCT00924937) according to the diabetic status.
Methods: 1002 patients were submitted to an oral fat load test meal (OFTT) with 0.7 g fat/kg body weight [12 % 
saturated fatty acids (SFA), 10 % polyunsaturated fatty acids (PUFA), 43 % monounsaturated fatty acids (MUFA), 10 % 
protein and 25 % carbohydrates]. Serial blood test analyzing lipid fractions were drawn at 0, 1, 2, 3 and 4 h during 
postprandial state. Postprandial triglycerides (TG) concentration at any point >2.5 mmol/L (220 mg/dL) has been 
established as undesirable response. We explored the dynamic response in 57 non‑diabetic, 364 prediabetic and 581 
type 2 diabetic patients. Additionally, the postprandial response was evaluated according to basal insulin resistance 
subgroups in patients non‑diabetic and diabetic without pharmacological treatment (N = 642).
Results: Prevalence of undesirable postprandial TG was 35 % in non‑diabetic, 48 % in prediabetic and 59 % in dia‑
betic subgroup, respectively (p < 0.001). Interestingly, prediabetic patients displayed higher plasma TG and large tria‑
cylglycerol‑rich lipoproteins (TRLs‑TG) postprandial response compared with those non‑diabetic patients (p < 0.001 
and p = 0.003 respectively). Moreover, the area under the curve (AUC) of TG and AUC of TRLs‑TG was greater in the 
prediabetic group compared with non‑diabetic patients (p < 0.001 and p < 0.005 respectively). Patients with liver 
insulin resistance (liver‑IR) showed higher postprandial response of TG compared with those patients with muscle‑IR 
or without any insulin‑resistance respectively (p < 0.001).
Conclusions: Our findings demonstrate that prediabetic patients show a lower phenotypic flexibility after external 
aggression, such as OFTT compared with nondiabetic patients. The postprandial response increases progressively 
according to non‑diabetic, prediabetic and type 2 diabetic state and it is higher in patients with liver insulin‑resist‑
ance. To identify this subgroup of patients is important to treat more intensively in order to avoid future cardiometa‑
bolic complications.
Keywords: Phenotypic flexibility, Triglycerides, Postprandial lipemia, Prediabetic, CORDIOPREV study, Insulin resistance
© 2016 Leon‑Acuña et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International 
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any 
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons 
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.
org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Cardiovascular Diabetology
*Correspondence:  pablopermar@yahoo.es 
†A. Leon‑Acuña, J. F. Alcala‑Diaz, P. Perez‑Martinez and J. Lopez‑Miranda 
contributed equally to this work
1 Lipid and Atherosclerosis Unit, IMIBIC/Reina Sofia University Hospital/
University of Cordoba, Cordoba, Spain
Full list of author information is available at the end of the article
Page 2 of 10Leon‑Acuña et al. Cardiovasc Diabetol  (2016) 15:68 
Background
Prediabetes status forms an intermediate stage in the 
natural history of type 2 diabetes mellitus (T2DM), and 
behaves a high risk of cardiovascular complications. 
It is estimated that 10  % of population have prediabe-
tes, although only one third know it. The average risk of 
development diabetes increases 0.7 % per year in people 
with normal glucose levels, and 5–10 % per year in pre-
diabetic patients [1]. Interestingly, at this stage of the dis-
ease, it is possible to return a normal state [2]. T2DM has 
been associated with abnormal postprandial lipoprotein 
metabolism, with a significant delay in the clearance of 
lipoproteins, including triglycerides (TG) and chylomi-
crons [3]. This fact could support the hypothesis to con-
sider T2DM as a systems disease with loss of flexibility 
in one or more metabolic processes involved. Therefore, 
the capacity to adapt in time and location to alterations 
in external factors, such as environmental conditions, is 
called phenotypic flexibility [4]. One biomarker of this 
phenotypic inflexibility is the degree of postprandial tri-
glyceride response. In this regard, the oral fat load test is 
a classic example of a challenge test [5] and the exagger-
ated response has been related to proatherogenic condi-
tions. Moreover clinical studies provide evidence that 
exposure to postprandial lipoproteins is associated with 
cardiovascular diseases [6, 7]. However at this point, lit-
tle is known about the role of postprandial lipemia in the 
prediabetes status. In fact, it is important to understand 
whether the underlying causes of metabolic inflexibility 
may influence the maintenance of overall triglycerides 
homoeostasis in the prediabetic status.
Based in this previous evidence, the aim of this study 
was examined the degree of postprandial lipemia 
response measured with the fat tolerance test accord-
ing to their diabetic status: prediabetic, non-diabetic and 
diabetic patients from the large cohort of CORDIOPREV 
clinical trial (NCT00924937). In a next step, we explored 
the postprandial response according to the presence or 
absence of muscle and/or liver insulin resistance.
Methods
Population
The current work was conducted within the framework 
of the CORDIOPREV study. The CORDIOPREV study is 
an ongoing prospective, randomized, opened, controlled 
trial including 1002 patients with coronary heart disease 
(CHD), which had their last coronary event more than 
6 months before of the enrolment in two different dietary 
models (Mediterranean and low-fat) over a period of 
5  years in addition to conventional treatment for coro-
nary heart disease [8].
Patients were recruited from November 2009 to 
February 2012, mostly at the Reina Sofia University 
Hospital (Cordoba, Spain), but other centers from the 
Cordoba and Jaen provinces were also included. Inclu-
sion and exclusion criteria have been reported pre-
viously [9]. In summary, patients were eligible if they 
were older than 20 years, but younger of 75, had estab-
lished CHD without clinical events in the last 6 months, 
were thought to follow a long-term dietary interven-
tion and did not have severe diseases or expected life 
expectancy lower than 5  years. Patients were catego-
rized depending on the presence of prediabetes crite-
ria, T2DM diagnosis or non-diabetes subgroup. Later, 
non-diabetic and diabetic patients without pharmaco-
logical treatment were divided in four groups accord-
ing the present of muscle and/or liver insulin resistance 
(IR): liver-IR, muscle-IR, insulin and muscle IR, with-
out liver or muscle-IR.
Criteria for prediabetes
Patients were classified according to American Diabetes 
Association (ADA) prediabetes criteria classification:
 – Impaired fasting glucose (IFG): 100  mg/dL 
(5.6 mmol/L) to 125 mg/dL (6.9 mmol/L) and/or
  – Impaired glucose tolerance (IGT): 2  h plasma glu-
cose in the 75  gr OGTT 140  mg/dL (7.8  mmol/L) to 
199 mg/dL (11 mmol/L) and/or
 – Hemoglobin glycated (HbA1c) plasma levels 5.7–6.4 %.
All patients gave written informed consent to partici-
pate in the study. The trial protocol and all amendments 
were approved by the local ethics committees, following 
the Helsinki declaration and the good clinical practices.
Study design
Before participants were enrolled in two different dietary 
models (Mediterranean diet and Low fat diet) from COR-
DIOPREV study, they received an oral fat tolerance test 
using a weight-adjusted meal (0.7 g fat and 5 mg choles-
terol per kg body weight) with 12 % saturated fatty acids 
(SFA), 10  % polyunsaturated fatty acids (PUFA), 43  % 
monounsaturated fatty acids (MUFA), 10 % protein and 
25  % carbohydrates (CHO). Meal preparation was per-
formed by a group of nutritionists with olive oil, skimmed 
milk, white bread, cooked egg yolks and tomatoes.
Methodology of the oral glucose tolerance test
Patients underwent a standard oral glucose tolerance test 
(OGTT) at baseline. After an overnight fast, blood was 
sampled from a vein before oral glucose intake (0-min) 
and then, after 75  gr flavoured glucose load (Trutol 75; 
Custom Laboratories, Baltimore, MD), blood samples 
were taken at 30, 60, 90 and 120  min to determine the 
glucose and insulin concentrations [10].
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Estimation of insulin resistance, insulin secretion and beta 
cell function indices
The indices used to determined tissue-specific IR were 
the validated hepatic insulin resistance index (HIRI) and 
the muscle insulin sensitibity index (MISI) [11]. HIRI 
was estimated by fasting insulin (mU/L) ×  fasting glu-
cose (mg/dL). MISI was measured MISI = (dG/dt)/mean 
plasma insulin concentration, where dG/dt is the rate 
of decay of plasma glucose concentration from its peak 
value to its nadir during the OGTT.
Determination of muscle and liver insulin resistance 
groups
At baseline, the patients were distributed into four 
groups according to the presence or absence of muscle 
and/or liver IR. For this purpose, we have used a method 
based on that described by Abdul-Ghani et al. [12]. The 
patients were divided into tertiles according their HIRI 
and MISI. The highest tertile of the HIRI and the low-
est tertile in MISI were considered to indicate IR in each 
organ respectively. A second operational definition based 
on the median value for IR in skeletal muscle and liver 
resulted in similar results.
Methodology of the oral fat tolerance test
Previously to the starting of the test, the patients had 
been fasting for 12  h and were asked to refrain from 
smoking during the fasting period and from alcohol 
intake during the preceding 7 days. They were also asked 
to avoid strenuous physical activity the day before the 
test given. At 8:00 a.m. patients presented in the labora-
tory, completed anthropometric (weight, height, waist 
circumference, BMI, blood pressure) and biochemi-
cal measurements, donated a fasting blood sample and 
under supervision, ingested the fatty food meal. The 
breakfast was eaten in 20 min. After the meal, volunteers 
were resting and consumed no food for 5  h, but were 
allowed to drink water. Blood samples for biochemical 
testing were collected before the meal and every hour 
during the next 4  h, following recommendations for an 
oral fat tolerance test proposed by Mihas et al. in a recent 
meta-analysis [13]. Postprandial TG concentration at any 
point >2.5 mmol/L (220 mg/dL) has been established as 
undesirable response [5].
Laboratory test
Venous blood was sampled from the antecubital vein and 
collected into vacutainer tubes with no anticoagulant and 
to tubes containing EDTA, and immediately transferred 
to 4 °C. To minimize proteolytic degradation, plasma was 
supplemented with protease inhibitor cocktail (Roche 
Diagnostic, Germany) 40  μL per mL of plasma. Plasma 
and serum samples were frozen at −80  °C for further 
biochemical analysis. Serum parameters were measured 
in Architect c-16000 analyzers (Abbott®, Chicago, Illi-
nois, USA) by spectrophotometric techniques (enzy-
matic colorimetric methods): hexokinase method for 
glucose, and oxidation-peroxidation for total cholesterol, 
HDL-C and triglycerides (TG). Plasma levels of insu-
lin were measured by chemiluminescent microparticle 
immunoassay using an analyzer (i-2000Abbott Architect 
®, Chicago, Illinois, USA). HOMA-IR was derived from 
fasting glucose and insulin levels [(fasting plasma glu-
cose × fasting serum insulin)/22.5]. As HOMA-IR takes 
into account both insulin and glucose levels, it may be a 
more complete index than plasma insulin. hsCRP were 
determined by high-sensitivity ELISA (BioCheck, Inc., 
Foster City, CA, USA) at the University College Dublin. 
Large triacylglycerol-rich lipoproteins fraction (TRL) 
containing chylomicrons and VLDL was removed from 
plasma by ultracentrifugation performed in a 70Ti fixed-
angle rotor (Beckman Instruments, Fullerton, CA, USA) 
at 30,000 rpm and 4 °C during 30 min at density <1.006 g/
mL.
Statistic analysis
All statistical analyses were made with PASW Statistics 
software, version 21.0.0. Continuous variables were com-
pared using Student’s “t” and the analysis of variance 
(ANOVA) depending on the existence of two or more 
groups in each comparison. When these variables did 
not follow a normal distribution, the required transfor-
mation of the data using for analysis the log10. Data are 
presented as mean ±  standard deviation for continuous 
variables and as frequencies or percentages for categori-
cal variables. Qualitative variables were compared using 
Chi square test. To determine the influence of predia-
betes in the postprandial metabolism, we used a general 
linear model of repeated measures of each postprandial 
parameter with the different groups, blood drawn time as 
within-subject variable and age, gender, BMI, waist cir-
cumference and pharmacological treatments as covari-
ates. We used total area under the curve (AUC) and 
delta (Δ) AUC of the different postprandial parameters 
following the trapezoid rule to assess the magnitude of 
change during postprandial state as in previous works 
of our group [14]. Bonferroni’s test was used in the post 
hoc analysis. All analyses were adjusted for potential con-
founders and p < 0.05 was considered to be significant.
Results
Baseline demographic and metabolic characteristics 
according to the patients are presented in Table 1. Age, 
BMI, waist circumference, HbA1c plasma levels, triglyc-
erides and HOMA-IR were statistically significant among 
groups (Table  1). We explored the dynamic response 
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according to the diabetic status in the CORDIOPREV 
population: 57 non diabetic, 364 prediabetic and 581 
diabetic.
We explored the dynamic response during the OFTT 
in order to identify those subjects with undesirable post-
prandial TG concentration at any point >2.5 mmol/L or 
220 mg/dL. Thus, the prevalence an unsiderable response 
after the OFTT was 35 % in non-diabetic, 48 % in predia-
betic, and 59 % in diabetic subgroup (p < 0.001) (Fig. 1). 
After the OFTT, diabetic patients showed greater post-
prandial response of TG (p < 0.001) and large triacylglyc-
erol-rich lipoproteins (TRLs)-TG (p =  0.002) compared 
with the prediabetic subgroup. Consistently, the AUC-TG 
and AUC TRLs-TG was significative greater in diabetic 
patients (p  <  0.001 and p  =  0.002 respectively) com-
pared with those prediabetic patients (Table 2). Interest-
ingly, prediabetic patients showed higher postprandial 
response compared with those non-diabetic (p < 0.001). 
Consequently, non-diabetic patients displayed lower 
postprandial response of TRLs-TG and AUC-TG, com-
pared with prediabetic and diabetic patients, (p = 0.003 
and p < 0.002) (Table 2).
In addition, the magnitude of the postprandial response 
increased progressively in relation to non-diabetic, pre-
diabetic and diabetic state groups (p < 0.001) (Fig. 2a, b). 
Moreover, AUC-TG and AUC TRLs-TG showed the same 
effect (p  <  0.001 and p  <  0.001 respectively) (Table  2). 
Likewise, diabetic patients compared with prediabetic 
and non-diabetic subgroups showed higher increase of 
AUC (iAUC) of TG and iAUC-TRLs-TG (p < 0.001 and 
p = 0.04 respectively).
Furthermore, the dynamic response was evaluated in 
non-diabetic patients and in diabetic patients without 
pharmacological treatment according to the different 
groups of baseline insulin resistance: liver-IR, muscle-
IR, liver and muscle-IR, non-liver and non-muscle-IR. 
Patients with liver insulin resistance (liver-IR) showed 
higher postprandial response of TG compared with those 
patients with muscle-IR or without any insulin-resistance 
respectively (p  <  0.001). No differences were observed 
according to the magnitude of postprandial response 
in group of patients with liver-IR group compared with 
those patients with liver-IR and muscle-IR (p  >  0.05) 
(Fig. 3). Pearson’s correlation and linear regression were 
used to associate postprandial response of TG and insu-
lin resistance indices variables: HIRI and MISI. Multi-
ple regression analysis using the AUC-TG as dependent 
variable showed a significant association with HIRI (R: 
0.309; CI 95 % (15327.162–24080.365); p < 0001). It has 
not been observed association between postprandial 
response and muscle-IR index. (p  >  0.05) (Fig.  4a, b). 
Similar results were obtained using iAUC-TG as depend-
ent variable. The analysis showed a significant association 
with HIRI (R: 0.2; IC 95 %: (4437.52–9238.68); p < 0.001). 
No significant association was observed between post-
prandial response and MIRI index (R: −0.012; IC 95  %: 
(−2047.05 to 1439.18); p =  0.732) (Fig.  4c). Finally, we 
explored the influence of pharmacological treatments 
Table 1 Baseline characteristics according to diabetic status
Values are mean ± SD. One way ANOVA
BMI body mass index, HbA1c glycated hemoglobin, hsCRP high sensitivity C‑reactive protein, HOMA-IR homeostatic model assessment insulin resistance, OGTT 
standard overload glucose tolerance test, HIRI hepatic insulin resistance index, MISI muscle insulin resistance index
* p < 0.05 posthoc Bonferroni analysis according three subgroups
Diabetic n = 581 Prediabetic n = 364 Non-diabetic n = 57 p value
Age (years old) 60.78 ± 8.67* 58.41 ± 9.28* 54.68 ± 8.39* 0.005
BMI 31.73 ± 4.54* 30.57 ± 4.26* 28.1 ± 4.54* 0.001
Waist circumference (cm) 107.14 ± 11.69* 103.32 ± 19.88* 96.59 ± 10* 0.001
HbA1c (%) 7.19 ± 1.26* 5.96 ± 0.28* 5.39 ± 0.21* 0.001
AST (mg/dL) 24.72 ± 16.67 26.31 ± 13.16 24 ± 6.37 0.219
ALT (mg/dL) 27.96 ± 23.73 28.58 ± 16.52 27.28 ± 13.88 0.136
Fasting triglycerides (mg/dL) 144.88 ± 72.72* 124.76 ± 62.81 105.75 ± 62,22 0.040
CRP (mg/dL) 2.76 ± 2.13 2.08 ± 1.86 1.61 ± 1.46 0.090
Insulin (mU/L) 12.51 ± 13.50 9.19 ± 6.60 6.92 ± 3.87 0.016
Serum ferritin (ng/mL) 97.45 ± 101.14 108.39 ± 100.77 114.58 ± 99.90 0.001
HOMA‑IR 5.49 ± 6.49* 2.13 ± 1.60* 1.56 ± 0.94* 0.001
Fasting glucose (mg/dL) 128.53 ± 44.24* 94.11 ± 10.24 81.18 ± 6.7 0.001
Glucose 2 h OGTT (mg/dL) 257.28 ± 108.35* 125.13 ± 38.35 106.11 ± 21.09 0.001
HIRI 2227.52 ± 2631.69* 1170.36 ± 904.67* 768.57 ± 406.98* 0.001
MIRI 0.025 ± 0.016 0.019 ± 0.021 0.022 ± 0.044 0.100
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(antihypertensives, statins, other hypolipidemic drugs, 
antiplaquelet, and antidiabetic drugs) on the magnitude 
of postprandial response and the results did not change. 
Discussion
Our findings support the hypothesis that prediabetic 
patients showed a lower degree of flexibility by an exag-
gerated lipoprotein postprandial response, compared 
with those non-diabetic patients. Moreover, in this large 
cohort we confirmed previous data indicating that dia-
betes status is associated with abnormal postprandial 
lipoprotein metabolism [15, 16]. Thus, the frequency of 
undesirable response increases progressively according 
to non-diabetic (35  %), prediabetic (48  %) and diabetic 
patients (59 %). The postprandial response was higher in 
patients with liver-IR compared with muscle-IR or with-
out any type of IR. Finally, our results indicate an associa-
tion between hepatic IR and postprandial-TG response.
Postprandial hypertriglyceridemia is consequence of 
several factors including genetic variations and medical 
conditions like obesity, metabolic syndrome and insulin 
resistance [17, 18]. During the postprandial period, intes-
tinal TRL are the main contributors to the serum lipid 
level. Hypertriglyceridemia can originate from decreased 
clearance or increased production of TRL. During lipid 
absorption, enterocytes produce and secrete chylomi-
crons and transiently store lipid droplets in the cytosol. 
The dynamic fluctuation of triglycerides in cytosolic lipid 
droplets suggests that they contribute to TRL produc-
tion and may thus control the length and amplitude of 
Fig. 1 Prevalence of undesirable postprandial triglycerides (TG) in the CORDIOPREV population according to diabetic status: non‑diabetic, predia‑
betic and diabetic subgroups. The black bars represent the percentage of patients with postprandial TG concentration at any point >220 mg/dL 
within each group
Table 2 Postprandial area under the curve (AUC) an incremental (iAUC) of TG and TRLs-TG according to the diabetes sta-
tus
Results are plotted as mean ± SE. Variables were compared using ANOVA with age, gender and BMI as covariates. Different letters express statistically significant 
differences with p value lower than 0.05. Values are mean ± SD. One way ANOVA
AUC-TG area under the curve of triglycerides, AUC of the large triacylglycerol‑rich lipoproteins (TRLs)‑TG, iAUC-TG incremental of the area under the curve of 
triglycerides, iAUC-TRLs-TG incremental of the area under the curve of the large triacylglycerol‑rich lipoproteins (TRLs)‑TG triglycerides
* p < 0.05 posthoc analysis according three subgroups
Diabetic n = 581 Prediabetic n = 364 Non Diabetic n = 57 p value
AUC‑TG 48153.31 ± 21486.26* 42542.64 ± 18250.47* 37612.5 ± 16874.66* 0.001
AUC TRLs‑TG 20319.69 ± 16633.45* 17064.00 ± 10771.03* 14970.29 ± 8080.98* 0.001
iAUC‑TG 14824.47 ± 10363.01* 13348.15 ± 8737.19 12284.71 ± 9291.00 0.038
iAUC‑TRLs‑TG 11801.26 ± 8184.73* 10628.53 ± 8179.69 9680.13 ± 6259.98 0.040
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the postprandial hypertriglyceridemia [19] Accumulation 
of TRLs in the postprandial state promotes the reten-
tion of remnant particles in the artery wall and for their 
size these particles cannot cross the endothelium as effi-
ciently as smaller LDL inducing accelerated atheroscle-
rosis [20]. In this regard, previous data have linked the 
exaggerated postprandial TG response to the incidence 
of coronary artery disease and stroke [21]. Moreover 
recent studies have demonstrated that diabetic patients 
present an exaggerated postprandial TG response after 
meals [22], and this phenomenon could be translated 
in a loss phenotypic flexibility and consequently in an 
increase of cardiovascular disease risk (CVD) [23]. In 
our large diabetic cohort, our findings consistently con-
firmed that the diabetic status is associated with an exag-
gerated postprandial response [15]. Recent data indicate 
that unlike the situation in the nondiabetic population, in 
which measurement of postprandial TG levels has been 
useful in identifying individuals at high CVD, specifically 
testing for postprandial TG level has shown considerably 
less promise in T2DM patients. However, the importance 
for testing postprandial lipemic response in prediabetic 
patients have not been established yet. According to epi-
demiological data, up to 70  % of individuals with pre-
diabetes will eventually develop diabetes. Likewise, data 























































Fig. 2 Evolution of (a) triglycerides (TG) and (b) large triacylglycerol‑rich lipoproteins (TRLs)‑TG after the oral fat tolerance test, according to the 
presence of prediabetes, non‑diabetes or diabetes state. Results are plotted as mean ± SD. Variables were compared using repeated measured 
ANOVA, with age, gender and BMI as covariates
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also convert back to normoglycaemia [24]. For this rea-
son, we decided to explore the prediabetes status, firstly 
because it is a reversible state with often asymptomathic 
period in its early stages [25] and secondly because sev-
eral trials have demonstrated reductions in the risk of 
developing diabetes among prediabetics after lifestyle 
and drug-based interventions [25–27]. In our study, 
we observed that prediabetic patients displayed higher 
plasma TG and TRLs-TG postprandial response com-
pared with those non-diabetic patients, suggesting that 
at this initial stage already have abnormal lipoprotein 
metabolism. A question arise about what is the main trig-
ger in this process: insulin resistance influencing post-
prandial lipoprotein response or instead the exaggerated 
postprandial response favouring the insulin resistance 
condition. In this context, the physiological link between 
these both process is not well understood. The hepatocel-
lular TG accumulation may be a direct cause of hepatic 
insulin resistance. The liver plays a unique role in the 
regulation of glucose homeostasis by maintaining blood 
glucose concentration within a normal range. However, 
impaired insulin action in the liver leads to insulin resist-
ance characterized by impairment in the ability of insulin 
to inhibit glucose output. Thus, liver insulin resistance 
which is the reduced sensitivity of the liver to insulin, 
causes gluconeogenesis and hyperglycemia. As a result of 
insulin resistance, the adipocyte increased release of free 
fatty acids (FFA) into the circulation. Increased FFA flux 
into the liver stimulates hepatic lipogenesis and promotes 
VLDL-TG overproduction, contributing to the pathogen-
esis of hypertriglyceridemia in diabetic population [28, 
29]. In this regards, recent studies exploring the effect of 
TRLs on insulin resistance during postprandial lipemia 
suggest that an exaggerated postprandial lipemia play 
an important role in the development of diabetes and 
its associated hepatic insulin resistance, but also in the 
development of whole body insulin resistance according 
of these mechanisms [30, 31]. Although the insulin resist-
ance develops simultaneously in multiple organs and it 
can be defined by different indices, [32] the importance 
of insulin resistance may differ among the different tis-
sues [33]. In our study we observed that those patients 
with liver-IR showed higher postprandial TG response 
compared with those with muscle-IR, and in addition, 
there was a significant association between postprandial 
response and hepatic insulin resistance defined by HIRI 
index. This finding is interesting because suggest that 
liver-IR appears to be a critical contributor factor of post-
prandial lipidemia.
From a clinical point of view, to recognize this inflexibil-
ity-subgroup of prediabetic patients with an exaggerated 
postprandial response may be important in terms of early 
identification of those at greatest risk who should be prior-
itized for lifestyle intervention according to clinical practice 
guidelines [34, 35]. In addition, recent studies have shown 
the possibility of modulating the postprandial response by 
Fig. 3 Evolution of triglycerides (TG) after the oral fat tolerance test according to the different basal insulin‑resistance groups: muscle‑IR and liver‑
IR, non muscle‑IR and non liver‑IR, liver‑IR and muscle‑IR. Results are plotted as mean ± SD. Variables were compared using repeated measured 
ANOVA, with age, gender and BMI as covariates
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Fig. 4 Dispersion diagram and regression line according to AUC‑TG and logarithm of HIRI (a) and MISI (b). Dispersion diagram and regression line 
according to iAUC‑TG and logarithm of HIRI (c)
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pharmacological treatments. This point can be the target of 
future studies in our population [36, 37]. The disadvantage is 
that the recognition of postprandial hypertriglyceridemia in 
the clinical setting has been severely hampered by technical 
difficulties and the lack of established clinical protocols for 
investigating postprandial lipemia. Although at this point 
there is no internationally agreed management for post-
prandial hypertriglyceridemia, a previous consensus has 
suggested a simple clinical protocol for investigating post-
prandial TG measurements, and has pointed out cut-offs 
for undesirable response [TG concentration  >2.5  mmol/L 
(220 mg/dL)] at any time after a OFTT meal. In this con-
text, in this study we explored, the frequency of undesirable 
postprandial TG response in each subgroup. As expected, 
diabetic patients commonly showed an undesiderable 
postprandial TG response and therefore will not benefit 
diagnostically from an OFTT. However, in the subgroup of 
prediabetic patients, half of them presented an exaggerated 
and delayed response and consequently they will benefit 
diagnostically from an OFTT.
In summary, this study demonstrate that prediabetic 
patients show a lower metabolic flexibility after external 
aggression, such as OFTT, compared with nondiabetic 
patients. The degree of postprandial response increases 
progressively according to non-diabetic, prediabetic and 
diabetic state and it is higher in patients with liver insulin-
resistance. To identify this subgroup of patients is impor-
tant to treat more intensively, according to ADA guidelines 
in order to avoid future cardiometabolic complications.
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